| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 07/09/2002 | US6416739 Microparticles and their therapeutic or diagnostic use |
| 07/09/2002 | US6416738 Administering to a recipient a first conjugate comprising a targeting moiety and a member of a ligand/anti-ligand binding pair, thereafter administering to the recipient a clearing agent, administering second conjugate |
| 07/09/2002 | US6416734 Recombinant alpha-fetoprotein for treating and diagnosing cancers |
| 07/09/2002 | CA2303132C Intranasal formulations containing scopolamine and method of treating motion sickness |
| 07/09/2002 | CA2273420C Matrix tablet permitting sustained release of gliclazide after oral administration |
| 07/09/2002 | CA2219475C Pharmaceutical composition of fenofibrate presenting a high biodisponibility and its preparation process |
| 07/09/2002 | CA2061566C Treatment of disease employing hyaluronic acid and nsaids |
| 07/09/2002 | CA2053468C Prolonged release preparation and polymers thereof |
| 07/08/2002 | CA2366780A1 Stabilized liquid preparation of the protease which activates blood coagulation factor vii, or of its proenzyme |
| 07/04/2002 | WO2002051994A2 Polypeptides |
| 07/04/2002 | WO2002051865A2 Proteinic antigens inducing antibodies neutralising hiv virus |
| 07/04/2002 | WO2002051800A2 Sulphur-containing amphiphilic agents for the transfer of biologically active molecules into cells |
| 07/04/2002 | WO2002051535A2 Preparation of microparticles having improved flowability |
| 07/04/2002 | WO2002051460A2 Bioactive materials for aneurysm repair |
| 07/04/2002 | WO2002051446A2 Transfection complexes (transoplex) having a reduced toxicity |
| 07/04/2002 | WO2002051445A2 An oral and parenteral pharmaceutical formulation comprising a low molecular weight thrombin inhibitor prodrug |
| 07/04/2002 | WO2002051444A1 Conjugates of integrin receptor antagonists and a cytostatic agent having specifically cleavable linking units |
| 07/04/2002 | WO2002051443A2 Aqueous gel comprising a gelling agent such as kappa carrageenan and at least 85 % water |
| 07/04/2002 | WO2002051436A2 Stable enzymatic wound debrider |
| 07/04/2002 | WO2002051432A1 A novel pharmaceutical compound and methods of making and using same |
| 07/04/2002 | WO2002051429A2 Use of a composition for the stimulation of nerve growth, the inhibition of scar tissue formation, the reduction of secondary damage and/or the accumulation of macrophages |
| 07/04/2002 | WO2002051421A2 Gel composition and trans-scrotal application of a composition for the treatment of hypogonadism |
| 07/04/2002 | WO2002051411A1 Famotidine injections |
| 07/04/2002 | WO2002051407A1 Thermoformable solid pharmaceutical composition for controlled release of perindopril |
| 07/04/2002 | WO2002051403A1 Compositions of stable t3 and methods of use thereof |
| 07/04/2002 | WO2002051390A2 Amphiphilic lipid nanoparticles for peptide and/or protein incorporation |
| 07/04/2002 | WO2002051387A1 Thermoformable solid pharmaceutical composition for controlled release of ivabradine |
| 07/04/2002 | WO2002051386A2 Lipid microparticles by cryogenic micronization |
| 07/04/2002 | WO2002051385A1 Solid dispersions of nitrate active principles |
| 07/04/2002 | WO2002051384A1 Method of stabilizing suspension and stabilized suspension |
| 07/04/2002 | WO2002051383A2 Controlled release of anti-arrhythmic agents from a biodegradable polyethylene oxide hydrogel for local application to the heart |
| 07/04/2002 | WO2002051380A1 Novel pharmaceutical composition consisting of water-soluble or poorly water-soluble active substances |
| 07/04/2002 | WO2002051378A1 Use of fluorinated solvents non-volatile at room temperature in cosmetic or pharmaceutical products |
| 07/04/2002 | WO2002051377A1 Water-in-oil emulsions containing one or more ammonium acryloyl dimethyltaurates or vinyl pyrrolidone copolymers |
| 07/04/2002 | WO2002051356A2 Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections |
| 07/04/2002 | WO2002051301A2 Fullerene (c60)-based x-ray contrast agent for diagnostic imaging |
| 07/04/2002 | WO2002033116A3 Nucleic acid ligands to the prostate specific membrane antigen |
| 07/04/2002 | WO2002026324A3 Tocol-based compositions containing amiodarone |
| 07/04/2002 | WO2002026233B1 Infusion of ciprofloxacin having reduced acid content and being stable in storage |
| 07/04/2002 | WO2002002076A3 Methods for treating inflammation-mediated conditions of the eye |
| 07/04/2002 | WO2002000870A3 Method for transfecting cells using a magnetic field |
| 07/04/2002 | WO2001092283A3 Cobalamin compounds useful as cardiovascular agents and as imaging agents |
| 07/04/2002 | WO2001091682A8 Composition and applicator for topical substance delivery |
| 07/04/2002 | WO2001082984A3 Low ionic strength ophthalmic compositions |
| 07/04/2002 | WO2001078768A3 Targeted vaccine delivery systems |
| 07/04/2002 | WO2001070770A3 Bisubstrate inhibitors of kinases |
| 07/04/2002 | WO2001036007A3 Compositions of a combination of radioactive therapy and cell-cycle inhibitors |
| 07/04/2002 | WO2001034099A9 Soy depigmenting and skin care compositions |
| 07/04/2002 | WO2000069900A9 Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| 07/04/2002 | US20020087205 Transcutaneous photodynamic treatment of targeted cells |
| 07/04/2002 | US20020086967 Controlled release polyacrylic acid granules and a process for preparing the same |
| 07/04/2002 | US20020086939 Method for the preparation of 1-benzotriazolyl carbonate esters of poly(ethylene glycol) |
| 07/04/2002 | US20020086905 Gel for treatment of skin diseases and for disinfection of the skin |
| 07/04/2002 | US20020086904 Methods of treating affective disorders using derivatives of (-)- venlafaxine |
| 07/04/2002 | US20020086897 Cytotoxic agents comprising taxanes and their therapeutic use |
| 07/04/2002 | US20020086896 Inhibiting stenosis or restenosis following vascular trauma in a mammalian host with cytoskeletal inhibitor comprising taxol, cytochalasin, or an analog thereof; implant coated or embedded with inhibitors for sustained release |
| 07/04/2002 | US20020086878 Monomolecular dispersions of various medicaments prepared for transmucosal delivery; treatment of respiratory illness such as cold and/or allergy |
| 07/04/2002 | US20020086849 Method for introducing antisense oligonucleotides into eucaryotic cells |
| 07/04/2002 | US20020086829 Peptide and plurality of linked ligands that together form a water insoluble complex |
| 07/04/2002 | US20020086819 Conjugating polymer (polyethylene glycol) to biologically active molecule (polypeptide); human urokinase plasminogen activator |
| 07/04/2002 | US20020086814 Selectively killing cells via targeting fragment of a toxin or lectin with photosensitizing agent, then exposing to light/radiation |
| 07/04/2002 | US20020086335 Nanoparticle for use as biosensors in the detection of nucleic acids, antigens, enzymes and enzyme substrates |
| 07/04/2002 | US20020086283 Immunogen |
| 07/04/2002 | US20020086061 Forming a drug containing core by compressing comprising granulated microparticles of felodipine and cyclodextrin, carrier comprising cyclodextrin particles, a water-insoluble alkaline component and a swellable polymer |
| 07/04/2002 | US20020086059 Dissolving solid material in dimethyl ether under a pressure and heating; reducing pressure on solution to precipitate the solid material as pulverous formulation and to expand dimethyl ether into a gas, separating |
| 07/04/2002 | US20020086057 For therapy of urinary incontinence |
| 07/04/2002 | US20020086052 Rapidly disintegrating methylcellulose tablets |
| 07/04/2002 | US20020086051 For delivering drug directly to interior portions of the body of a mammalian organism, such as to the eye |
| 07/04/2002 | US20020086049 Apoptosis-mimicking synthetic entities and use thereof in medical treatment |
| 07/04/2002 | US20020086029 For use in inhibiting gastric acid secretion; therapy of gastric acid related diseases |
| 07/04/2002 | US20020085990 Osmotic amount of polyethylene glycol (PEG) 3350, or PEG 4000, and a pharmaceutically acceptable effervescent coupling system. |
| 07/04/2002 | US20020085989 Process of making a compound by forming a polymer from a template drug |
| 07/04/2002 | US20020085978 Containing a propellant, a cosolvent, and a radical quencher. |
| 07/04/2002 | DE10065047A1 Gelcèmes in Form von O/W-Emulsionen mit einem Gehalt an einem oder mehreren Ammoniumaryloyldimethyltaurat/vinylpyrrolidoncopolymeren Gelcèmes in the form of O / W emulsions with a content of one or more Ammoniumaryloyldimethyltaurat / vinylpyrrolidoncopolymeren |
| 07/04/2002 | DE10065046A1 O/W-Emulsionen mit einem Gehalt an einem oder mehreren Ammonium acryloyldimethyltaurat/Vinylpyrrolidoncopolymeren O / W emulsions containing one or more ammonium acryloyldimethyltaurate / Vinylpyrrolidoncopolymeren |
| 07/04/2002 | DE10065045A1 W/O-Emulsionen mit einem Gehalt an einem oder mehreren Ammoniumacryloyldimethyltaurat/Vinylpyrrolidoncopolymeren W / O emulsions with a content of one or more ammonium acryloyldimethyltaurate / Vinylpyrrolidoncopolymeren |
| 07/04/2002 | DE10062747A1 Koppelmittel zum schmerzreduzierten Einleiten von Schallwellen vor allem in den menschlichen Körper Coupling means for pain reduced discharge of sound waves, especially in the human body |
| 07/04/2002 | CA2782510A1 Polypeptides |
| 07/04/2002 | CA2433861A1 Controlled release of anti-arrhythmic agents from a biodegradable polyethylene oxide hydrogel for local application to the heart |
| 07/04/2002 | CA2433116A1 Conjugates of integrin receptor antagonists and a cytostatic agent having specifically cleavable linking units |
| 07/04/2002 | CA2433081A1 Bioactive materials for aneurysm repair |
| 07/04/2002 | CA2432896A1 Thermoformable solid pharmaceutical composition for controlled release of perindopril |
| 07/04/2002 | CA2432645A1 Thermoformable solid pharmaceutical composition for controlled release of ivabradine |
| 07/04/2002 | CA2432523A1 Compositions of stable t3 and methods of use thereof |
| 07/03/2002 | EP1219306A1 Compositions comprising cyclodextrins and NO- releasing drugs |
| 07/03/2002 | EP1219305A1 Conjugates of integrin receptor antagonists and a cytostatic agent having specifically cleavable linking units |
| 07/03/2002 | EP1219304A2 Stable parenteral solution containing diclofenac salts, their preparation and use therof |
| 07/03/2002 | EP1219293A2 Pharmaceutical aerosol compostion |
| 07/03/2002 | EP1218889A2 Controlled release compositions comprising nimesulide |
| 07/03/2002 | EP1218498A1 Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles |
| 07/03/2002 | EP1218496A2 DIAGNOSTIC PROBES AND THERAPEUTICS TARGETING uPA AND uPAR |
| 07/03/2002 | EP1218484A1 Elastic article |
| 07/03/2002 | EP1218425A1 Microbicidal additives |
| 07/03/2002 | EP1218413A2 Engineering antibodies that bind irreversibly |
| 07/03/2002 | EP1218393A1 Cell targeting compositions and methods of using the same |
| 07/03/2002 | EP1218035A2 Rapid peg-modification of viral vectors |
| 07/03/2002 | EP1218034A2 Binding agents |
| 07/03/2002 | EP1218026A2 Method to enhance healing of sternum after sternotomy |
| 07/03/2002 | EP1218023A2 Method for calming human beings using personal care compositions |
| 07/03/2002 | EP1218013A2 Phospholipid prodrugs of anti-proliferative drugs |